期刊文献+

β淀粉样蛋白膜内片段免疫APP转基因小鼠的脑组织学变化研究 被引量:1

Influence of intramembranous fragment of amyloid-β on APP Tg mice
下载PDF
导出
摘要 目的从组织病理学的角度分析不同剂量的淀粉样蛋白膜内片段(intramembranous fragments of amyloid-β,IF-Aβ)对淀粉样前体蛋白(amyloid precursor protein,APP)转基因(transgenic,Tg)小鼠的影响,以确定IF-Aβ疫苗是否对APP Tg小鼠有治疗作用。方法 1)分别用PBS、KLH-IF-Aβ(50μg/只)、KLH-IF-Aβ(100μg/只)和KLH-Aβ42(100μg/只)免疫对照组、IF50组、IF100组和Aβ42组6月龄APP Tg C57BL/6J小鼠,共4次,2.5月;2)ELISA检测血清和脑组织IgG抗体;3)水迷宫检测APP Tg小鼠认知功能变化;4)免疫组化检测模型鼠大脑老年斑的变化;5)HE染色和电镜技术检测小鼠海马组织。结果免疫2.5个月后:1)IF-Aβ疫苗对APP转基因小鼠具有良好的体液免疫原性;2)IF50组小鼠的认知功能加强,大脑皮层区老年斑有所减少,较对照组海马区域组织学有所改善;3)IF100组小鼠的认知功能下降,大脑皮层老年斑明显减少,但组织学观察海马区域损伤加重;4)Aβ42组小鼠认知功能有所提高,大脑皮层老年斑明显减少,组织学观察海马区域损伤有所加重。结论在合适的免疫剂量下,小鼠认知功能的变化和海马区域神经元的损伤情况以及老年斑变化一致;而免疫剂量过大,虽然老年斑减少,但是小鼠的神经组织和细胞损伤加重,认知功能下降。 In this study,the effects of different doses of intramembranous fragments of amyloid-β(IF-Aβ) on amyloid precursor protein(APP) transgenic(Tg) mice were analyzed by pathology-signs observation,to determine appropriate doses of IF-Aβ which would exert therapeutic effects on APP Tg mice.Water maze test indicated that administration of IF-Aβ(50 and 100 μg/mouse respectively) to APP Tg C57BL/6J mice at age of 6 months for 2.5 months could alleviate cognitive impairments which accompanied with decreased Aβ deposition in the brain regions;a histological analysis with immunohistochemistry,HE,and ultrastructural observation suggested that a appropriate immune dose could improve cognitive function and decrease senile plaque of mice;when immune dosage is too large,although the senile plaque decreases,but the neural tissue and cell injury increases and the cognitive function declines in mice.
出处 《免疫学杂志》 CAS CSCD 北大核心 2013年第10期845-849,共5页 Immunological Journal
基金 2010年河南省重点科技攻关项目(102102310327)
关键词 Β淀粉样蛋白 免疫 病理 Amyloid-β Immune Pathology
  • 相关文献

参考文献10

  • 1Schenk D,Barbour R,Dunn W,et al.Immunization withamyloid-beta attenuates Alzheimer-disease-like pathologyin the PDAPP mouse [J].Nature,1999,400(6740):173-177.
  • 2Janus C,Pearson J,Mclaurin J,et al.Aβ peptideVimmunization reduces behavioral impairment and plaquesin a model of Illzheimer's disease[J].Nature,2000,408(15):979-982.
  • 3Zhang YH,Raymick J,Sarkar S,et al.Efficacy and toxicityof clioquinol treatment and A-beta42 inoculation in theAPP/PSI mouse model of Alzheimer's disease [J].CurrAlzheimer Res,2013,10(5):494-506.
  • 4张松江,邬力祥.淀粉样蛋白膜内片段疫苗对APP转基因小鼠的治疗研究[J].免疫学杂志,2011,27(9):764-768. 被引量:2
  • 5Guan X,Zou J,Gu H,et al.Short amyloid-p immunogenswith spacer-enhanced immunogenicity without junctionalepitopes for Alzheimer's disease immunotherapy [J].Neuroreport,2012,23(15):879-884.
  • 6Men6ndez Gonzalez M,Perez Pinera P,Martinez Rivera M,et al.Immunotherapy for Alzheimer's disease:rational basisin ongoing clinical trials [J].Curr Pharm Des,2011,17(5):508-520.
  • 7Lambracht Washington D,Qu BX,Fu M.et al.A peptideprime-DNA boost immunization protocol provides significantbenefits as a new generation Ap42 DNA vaccine forAlzheimer disease[J].J Neuroimmunol,2013,254(1/2):63-68.
  • 8Asuni A A,Boutajangout A,Scholtzova H,et al.Vaccinationof Alzheimer's model mice with Ap derivative in alumadjuvant reduces Ap burden without microhemorrhages [J].Eur J Neurosci,2006,24(9):2530-2542.
  • 9Agadjanyan MG,Ghochikyan A,Petrushina I,et al.Prototype Alzheimer's disease vaccine using theimmunodominant B cell epitope from beta-amyloid andpromiscuous T cell epitope pan HLA DR-bindingpeptide[J].J Immunol,2005,174⑶:1580-1586.
  • 10Olkhanud PB,Mughal M,Ayukawa K,et al.DNAimmunization with HBsAg-based particles expressing a Bcell epitope of amyloid p-peptide attenuates diseaseprogression and prolongs survival in a mouse model ofAlzheimer's disease[J].Vaccine,2012,30(9):1650-1658.

二级参考文献10

  • 1Hardy J,Selkoe DJ.The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science . 2002
  • 2Schenk D,Barbour R,Dunn W,et al.Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature . 1999
  • 3Janus C,Pearson J,McLaurin J,et al.A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature . 2000
  • 4Orgogozo JM,Gilman S,Dartigues JF,et al.Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology . 2003
  • 5Lemere CA,Spooner ET,Leverone JF,et al.Intranasal immunotherapy for the treatment of Alzheimer’s disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiology of Aging . 2002
  • 6S Salloway,J Mintzer,MF Weiner.Disease-modifying therapies in Alzheimer’s disease. Alzheimers Dement . 2008
  • 7T Wisniewski,U Konietzko.Amyloid-β immunisation for Alzheimer’s disease. The Lancet Neurology . 2008
  • 8Cribbs DH,Ghochikyan A,Vasilevko V,et al.Adjuvant-de-pendent modulation of Th1 and Th2 responses to immunizationwithβ-amyloid. International Immunology . 2003
  • 9赵振富,苏雪莹,初国良,汪华侨,徐杰,姚志彬.β-淀粉样蛋白特异性单链抗体的制备及鉴定[J].免疫学杂志,2010,26(3):215-219. 被引量:6
  • 10常洋,秦川,尹红星,朱华,蔡有余.建立阿尔茨海默症的转基因动物模型[J].解剖学报,2000,31(2):144-147. 被引量:38

共引文献1

同被引文献12

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部